@-Health, a company specializing in e-cardiology, will be participating for the first time at CES, to be held from January 9-12, 2018, in Las Vegas, Nevada. With the support of French Tech Aix-Marseille, the Aix-based company will present CardioNexion, the first connected medical device for early detection and analysis, in real-time and continuously, of all cardiovascular pathologies.
Cardiovascular disease is the leading cause of death worldwide, according to WHO. In response to this global public health challenge, @-Health is setting its sights on being a leading player. By participating in CES 2018, the company intends to demonstrate the relevance of CardioNexion to U.S. investors and potential partners.
CardioNexion can detect any pathology with the initial symptom as a change in heart rate. This includes stroke, atrial fibrillation, heart failure, sudden infant death and influenza. The system also represents a new tool for practitioners, allowing the attending physician to prescribe appropriate treatment and control its effectiveness in real time.
The patient wears the device as a T-shirt or bra embedded with smart sensors that continuously monitor cardiac function. This totally ambulatory, non-invasive and autonomous device delivers the same medical supervision as in an intensive care unit. Data are transmitted via the patient’s smartphone to secure servers for analysis with a proprietary algorithm. The information is then transferred to a surveillance platform where a team of cardiologists and intensive care unit nurses are ready to respond. If a problem is detected, the patient's doctor is notified. In the most serious cases, "911" is directly called.